You are here
-
SOX10 [SOX10/1074]
Description SOX10 is a member of the SOX (SRY-related HMG-box) family of transcription factors involved in the regulation of embryonic development and in the determination of cell fate. During development, SOX10 first appears in the forming neural crest and continues to be expressed in Schwann cells. It is important for differentiation, maturation and maintenance of Schwann cells and melanocytes. In normal tissues, SOX10 is expressed in Schwann cells and glial cells in the nervous system. It is also detected in melanocytes and epithelial cells of salivary gland and mammary gland. In tumor tissues, SOX10 labels melanoma and the tumor of neural crest origin. A recent study reported the expression of SOX10 in basal-like, unclassified triple-negative breast carcinoma. Thus, breast carcinoma must be considered in the differential diagnosis of melanoma for a SOX10-positive metastatic malignant neoplasm. (Shipping Cost: €200.00) Host Mouse Application Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse 
7 ml more info 
14 days 
€187,20 Add to cart -
SOX11 [MRQ-58]
Description Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature B-cell neoplasms and is an aggressive disease genetically characterized by overexpression of cyclin D1 (CCND1), an important regulator of the G1/S phase of the cell cycle, due to the specific translocation t(11;14)(q13;q32). Cyclin D1 overexpression is the hallmark of MCL. However, approximately 5%-10% of MCLs lack cyclin D1 expression and may be misdiagnosed by overreliance on cyclin D1 IHC. Recently, SOX-11 protein expression in MCL has been investigated by immunohistochemistry. Two studies have evaluated SOX-11 expression in MCL and found strong nuclear expression of SOX-11 in almost all cyclin D1-positive MCL (93%-100%). In all 13 cases of cyclin D1-negative MCL, SOX-11 was strongly expressed. The authors also found that blastoid variant of MCL can be differentiated from CD5+ diffuse large B cell lymphoma, which was negative for SOX-11. In summary, nuclear protein expression of SOX-11 is highly associated with both cyclin Host Mouse Application Immunohistochemistry (IHC) Reactivity Human
1 ml more info 14 days
€520,00 Add to cart -
SOX11 Polyclonal
Description Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature B-cell neoplasms and is an aggressive disease genetically characterized by overexpression of cyclin D1 (CCND1), an important regulator of the G1/S phase of the cell cycle, due to the specific translocation t(11;14)(q13;q32). Cyclin D1 overexpression is the hallmark of MCL. However, approximately 5%-10% of MCLs lack cyclin D1 expression and may be misdiagnosed by overreliance on cyclin D1 IHC. Recently, SOX-11 protein expression in MCL has been investigated by immunohistochemistry. Two studies have evaluated SOX-11 expression in MCL and found strong nuclear expression of SOX-11 in almost all cyclin D1-positive MCL (93%-100%). In all 13 cases of cyclin D1-negative MCL, SOX-11 was strongly expressed. The authors also found that blastoid variant of MCL can be differentiated from CD5+ diffuse large B cell lymphoma, which was negative for SOX-11. In summary, nuclear protein expression of SOX-11 is highly associated with both cyclin Host Rabbit Application Peptide ELISA, Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse,Rat, Bovine,Pig (Porcine) 
1 ml more info 14 days
€374,40 Add to cart -
SOX11 Polyclonal
Description Mantle cell lymphoma (MCL) accounts for 5% to 10% of mature B-cell neoplasms and is an aggressive disease genetically characterized by overexpression of cyclin D1 (CCND1), an important regulator of the G1/S phase of the cell cycle, due to the specific translocation t(11;14)(q13;q32). Cyclin D1 overexpression is the hallmark of MCL. However, approximately 5%-10% of MCLs lack cyclin D1 expression and may be misdiagnosed by overreliance on cyclin D1 IHC. Recently, SOX-11 protein expression in MCL has been investigated by immunohistochemistry. Two studies have evaluated SOX-11 expression in MCL and found strong nuclear expression of SOX-11 in almost all cyclin D1-positive MCL (93%-100%). In all 13 cases of cyclin D1-negative MCL, SOX-11 was strongly expressed. The authors also found that blastoid variant of MCL can be differentiated from CD5+ diffuse large B cell lymphoma, which was negative for SOX-11. In summary, nuclear protein expression of SOX-11 is highly associated with both cyclin Host Rabbit Application Peptide ELISA, Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse,Rat, Bovine,Pig (Porcine)
7 ml more info 14 days
€187,20 Add to cart -
SOX2 [MD113R]
Description Anti-SOX2 recognizes lung squamous cell carcinoma (LSCC). Extensive anti-SOX-2 staining is seen in over 90% of LSCC and largely parallels p63 expression. However, only 4.5% of lung adenocarcinoma (LACA) is positive for SOX-2. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. Anti-CK 5&6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK 5&6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK 5&6+/ anti-p63+/anti-SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced mode Host Rabbit Application Immunohistochemistry (IHC) Reactivity Human
1 ml more info 14 days
€416,00 Add to cart -
SOX2 [MD113R]
Description Anti-SOX2 recognizes lung squamous cell carcinoma (LSCC). Extensive anti-SOX-2 staining is seen in over 90% of LSCC and largely parallels p63 expression. However, only 4.5% of lung adenocarcinoma (LACA) is positive for SOX-2. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. Anti-CK 5&6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK 5&6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK 5&6+/ anti-p63+/anti-SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced mode Host Rabbit Application Immunohistochemistry (IHC) Reactivity Human
7 ml more info 14 days
€214,50 Add to cart -
SOX2 [SOX2/1791]
Description Anti-SOX2 recognizes lung squamous cell carcinoma (LSCC). Extensive anti-SOX-2 staining is seen in over 90% of LSCC and largely parallels p63 expression. However, only 4.5% of lung adenocarcinoma (LACA) is positive for SOX-2. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. Anti-CK 5&6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK 5&6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK 5&6+/ anti-p63+/anti-SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced mode Host Mouse Application ELISA, Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse
1 ml more info 14 days
€374,40 Add to cart -
SOX2 [SOX2/1791]
Description Anti-SOX2 recognizes lung squamous cell carcinoma (LSCC). Extensive anti-SOX-2 staining is seen in over 90% of LSCC and largely parallels p63 expression. However, only 4.5% of lung adenocarcinoma (LACA) is positive for SOX-2. In a study by Sholl et al, 29% of LACA cases exhibited at least focal p63 expression. Combined p63 and SOX-2 expression was seen in 94% of LSCC and 12% of LACA with a statistically significant difference (P<0.0001) versus p63 alone. Anti-CK 5&6 had a good sensitivity but poor specificity for LSCC. Combined anti-CK 5&6 and anti-p63 positivity was seen in 93% of LSCC and 24% of LACA. Anti-CK 5&6+/ anti-p63+/anti-SOX-2+ was detected in 93% of LSCC and only 9% of LACA. These results indicate that the sensitivity of anti-p63 is equally high but its specificity is similarly variable; it was seen at least focally in close to 30% of LACA. When used together, anti-p63+/anti-SOX-2+ applied to the same tumor cell population is >90% specific for LSCC. Anti-SOX-2 produced mode Host Mouse Application ELISA, Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse
7 ml more info 14 days
€187,20 Add to cart -
SOX9 [MD19R]
Description Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY. Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification. Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination. In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells, hair follicle stem cells, and mammary stem cells. Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells. Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like pr Host Rabbit Application Immunocytochemistry (ICC),Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse
1 ml more info 14 days
€442,00 Add to cart -
SOX9 [MD19R]
Description Sox9 is a transcription factor with an HMG-box DNA binding domain that has homology to the HMG domain of the mammalian testis-determining factor, SRY. Sox9 regulates several important processes during embryonic development including chondrogenesis, during which it contributes to skeletal formation and digit specification. Sox9 also coordinates with steroidogenic factor-1 to direct Sertoli cell-specific expression of anti-Mullerian hormone during embryogenesis, thereby contributing to male sex determination. In addition, Sox9 is reportedly involved in the maintenance of adult stem cell populations, including multipotent neural stem cells, hair follicle stem cells, and mammary stem cells. Recent interest has focused on the role of Sox9 in tumor biology. For example, research studies have shown that Sox9 expression in lung adenocarcinoma induces a mesenchymal phenotype in tumor cells. Other research studies have shown that YAP1 induced upregulation of Sox9 confers cancer stem cell like pr Host Rabbit Application Immunocytochemistry (ICC),Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blot (WB) Reactivity Human, Mouse
7 ml more info 14 days
€234,00 Add to cart
